Evidence map›Paper›PMID 39492583›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2024

[Advances on Molecular Mechanism and Clinical Treatment 
in Invasive Mucinous Adenocarcinoma].

Minjun Shi, Bo Ye

Abstract readReviewEnglish Abstract
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Minjun ShiDepartment of Thoratic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 
Shanghai 200030, China.
Bo YeDepartment of Thoratic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 
Shanghai 200030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive mucinous adenocarcinoma (IMA) is a special type of lung adenocarcinoma that accounts for 2% to 10% of all lung adenocarcinoma. Surgical treatment is preferred for IMA, and traditional chemotherapy drugs and targeted therapy drugs have poor efficacy in this disease. IMA has unique prognostic, imaging and molecular features. The incidence of IMA is very low, so thoracic surgeons may lack of knowledge to the disease and misdiagnose it as benign diseases such as pneumonia and tuberculosis. This article reviews and discusses the imaging, clinicopathological features, treatment methods and prognosis of IMA.
.

Indexed as

Adenocarcinoma, MucinousLung NeoplasmsHumansNeoplasm InvasivenessPrognosisInvasive mucinous adenocarcinomaLung neoplasmsMolecule mechanismTreatment

Identifiers

PMID39492583
PMCPMC11534550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.